Provided are pharmaceutical compositions comprising a pharmaceutically effective amount of a steroid and a pharmaceutically effective amount of at least one modulator selected from the group consisting of a transient receptor potential (TRP) channel modulator and a proliferatior-activated receptor (PRP) modulator, wherein cannabidiol is not present as the sole modulator, and uses thereof for treating a condition or a symptom thereof, wherein said condition involves inflammation, an immune disease, an autoimmune disease or a combination thereof.

The present disclosure provides a pharmaceutical composition for multi-stage release of psychoactive substances including cannabinoids. The pharmaceutical composition comprises two or more staged compositions having different release profiles or different release time such that the one or more active agents in each of the two or more staged compositions are released into the subject's blood stream at different time points.

The present disclosure provides a pharmaceutical composition for multi-stage release of psychoactive substances including cannabinoids. The pharmaceutical composition comprises two or more staged compositions having different release profiles or different release time such that the one or more active agents in each of the two or more staged compositions are released into the subject's blood stream at different time points.

The present invention discloses a nutraceutical composition for up-regulation of SIRT 1 expression. The nutraceutical composition comprises NMN at in an amount between 300 mg and 500 mg, in an amount of 500 mg, and a soluble agent. The NMN and polyphenol are wrapped in a soluble agent as a protective bio-active agent to increase bioavailability and protect the polyphenol compounds during gut absorption. The invention also discloses a method of preparing a nutraceutical composition by weighing polyphenol at a suitable concentration, mixing the polyphenol with a suitable soluble agent and finally adding NMN to the mixture and blended it to form the nutraceutical composition. The nutraceutical composition up regulates SIRT1 and hence is suitable for treatment of various diseases and used in the form of powder, liquid, tablets, capsules, chewable form, gels, etc.

The present invention discloses a nutraceutical composition for up-regulation of SIRT 1 expression. The nutraceutical composition comprises NMN at in an amount between 300 mg and 500 mg, in an amount of 500 mg, and a soluble agent. The NMN and polyphenol are wrapped in a soluble agent as a protective bio-active agent to increase bioavailability and protect the polyphenol compounds during gut absorption. The invention also discloses a method of preparing a nutraceutical composition by weighing polyphenol at a suitable concentration, mixing the polyphenol with a suitable soluble agent and finally adding NMN to the mixture and blended it to form the nutraceutical composition. The nutraceutical composition up regulates SIRT1 and hence is suitable for treatment of various diseases and used in the form of powder, liquid, tablets, capsules, chewable form, gels, etc.

Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).

Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).

Methods and formulations for batch-mixing flavonoid tinctures and infusing the flavonoid batch-mixed tincture into a food, beverage, cosmetic or drug products with minimal or no effect on the alcohol by volume of the product, and to precisely deliver the desired mixture concentration of the flavonoids, is provided. A batch-mixed flavonoid tincture includes an amount of at least two individual flavonoid tinctures, each flavonoid tincture being a mixture of at least a flavonoid and a solvent. The batch-mixed tincture is added to various food and beverages, or alternatively directly administered to a human or animal, to make a bioavailable amount of flavonoids to be absorbed and metabolized by the body providing demonstrated health benefits.

Methods and formulations for batch-mixing flavonoid tinctures and infusing the flavonoid batch-mixed tincture into a food, beverage, cosmetic or drug products with minimal or no effect on the alcohol by volume of the product, and to precisely deliver the desired mixture concentration of the flavonoids, is provided. A batch-mixed flavonoid tincture includes an amount of at least two individual flavonoid tinctures, each flavonoid tincture being a mixture of at least a flavonoid and a solvent. The batch-mixed tincture is added to various food and beverages, or alternatively directly administered to a human or animal, to make a bioavailable amount of flavonoids to be absorbed and metabolized by the body providing demonstrated health benefits.

Methods and formulations for batch-mixing flavonoid tinctures and infusing the flavonoid batch-mixed tincture into a food, beverage, cosmetic or drug products with minimal or no effect on the alcohol by volume of the product, and to precisely deliver the desired mixture concentration of the flavonoids, is provided. A batch-mixed flavonoid tincture includes an amount of at least two individual flavonoid tinctures, each flavonoid tincture being a mixture of at least a flavonoid and a solvent. The batch-mixed tincture is added to various food and beverages, or alternatively directly administered to a human or animal, to make a bioavailable amount of flavonoids to be absorbed and metabolized by the body providing demonstrated health benefits.